Supplementary figure 1 A) Microarray heat map comparing mRNA expression of several genes involved in regulating the Wnt pathway between WT and PMCA4 -/-fibroblasts. B) qRT-PCR analysis showing increased IGFBP4 and (C) IGFBP5 mRNA levels in PMCA4 -/-cardiac fibroblasts (n=4 in each group, *P<0.05, Student's t-test). All error bars represent the SEM. 
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Supplementary figure 3 A) Expression of hypertrophic marker ANP in the hearts of WT and PMCA4 -/-mice following TAC (WT Sham, n=4, WT TAC, n=4, KO sham n=5, KO TAC, n=4; *P<0.05, one way Anova). B) Analysis of dP/dt max and (C) dP/dt min showed no difference in cardiac contractility between WT and PMCA4 -/-mice after 5 weeks of TAC (n= 10 in each group). D) Expression of TCF4, a b-catenin target gene, was significantly reduced in PMCA4 -/-TAC mice compared to WT-TAC group (WT Sham, n=4, WT TAC, n=4, KO sham n=5, KO TAC, n=4;*P<0.05, one way Anova). E) Analysis of heart weight/tibia length ratio following 4 weeks swimming exercise showed no difference between WT and PMCA4 -/-mice (n=7 in each group). F) Representative images of Masson's trichrome staining and (G) quantification of fibrotic area indicated that there was no difference in the fibrosis level between PMCA4 -/-and WT controls (scale bars= 50mm; NS=not significant). Error bars represent SEM. Supplementary figure 11 Analysis of (A) alanine transaminase (ALT) and aspartate transaminase (AST) and B) creatinine level in the serum of C57Bl/6 mice treated with vehicle or ATA (5mg per kg BW per day) for 4 weeks. ALT, AST and creatinine levels were detected using commercially available kit (Abcam). (Vehicle, n=4, ATA, n=5; NS=not statistically significant by student's t-test). All error bars represent the SEM. 
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